Slides
Page 1
Investor Presentation November 2025
Page 2
Safe harbour Putting Science to Work 2 Certain statements in this release concerning our future growth prospects are forward-looking statements, which are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those contemplated in such forward-looking statements. Important factors that could cause actual results to differ materially from our expectations include, amongst others general economic and business conditions in India, business outlook of our clientele and their research and development efforts, our ability to successfully implement our strategy, our growth and expansion plans and technological changes, changes in the value of the Rupee and other currencies, changes in the Indian and international interest rates, change in laws and regulations that apply to the Indian and global biotechnology and pharmaceuticals industries, increasing competition, changes in political conditions in India and changes in the foreign exchange control regulations in India. Neither the Company, nor its directors and any of the affiliates have any obligation to update or otherwise revise any statements reflecting circumstances arising after this date or to reflect the occurrence of underlying events, even if the underlying assumptions do not come to fruition.
Page 3
Contents Putting Science to Work 3 2 Syngene – Putting Science to Work 3 Syngene strengths 4 Financials 5 Shareholding and Share Information 1 Q2 FY26 Highlights
Page 4
1 Q2 FY26 Highlights
Page 5
Q2 and H1 FY26 performance Operating Highlights Putting Science to Work 5 Revenue from Operations Rs 911 Cr ( 2% Y-o-Y) ~USD 103 Mn Operating EBITDA margin 22% (27% in Q2 FY25) Reported PAT before exceptional items: (-37%YoY) Q2 FY26 Financial Highlights • The Company secured its first global phase III clinical trial from a U.S.-based biotech company. The trial will recruit patients across clinical sites in India and the U.S., reflecting Syngene’s growing capabilities in the global clinical trials market. • Syngene has also expanded its clinical trials footprint to Australia, New Zealand, the UK, Sri Lanka, and Eastern Europe, strengthening global trial execution capabilities through strategic partnerships with well-established CROs in these regions. • Syngene will expand its biologics facility in Bengaluru with a GMP bioconjugation suite to provide fully integrated, end-to-end manufacturing of ADCs. The suite will accelerate development timelines by enabling both Monoclonal Antibodies (mAb) production and GMP bioconjugation at a single site and complement Syngene’s existing commercial capabilities in payload and linker manufacturing. • Progress at the Bayview biologics manufacturing facility in the U.S. remains on track, with revalidation, integration, and staff recruitment advancing towards operationalization in the second half of the year. • The sustainability assessment of Syngene’s laboratories, conducted by US sustainability certification expert, My Green Lab (MGL), earned the highest level ‘Green Certification’ with a score exceeding 94%. Further, Syngene strengthened its position as a global sustainability leader, with its EcoVadis 2025 score rising to 74/100, up from 66 last year. This places the Company in the 91st percentile, ranking it among the top companies worldwide for sustainability practices.. H1 FY26 Financial Highlights Revenue from Operations Rs 1,785 Cr ( 6% Y-o-Y) ~USD 204 Mn Operating EBITDA margin 23% (25% in H1 FY25) Reported PAT before exceptional items: ( -4% YoY)
Page 6
2 Syngene – Putting Science to Work
Page 7
Partner in innovation: #Putting Science to Work Putting Science to Work 7 Who we are and what we do We aim to be a world class partner delivering innovative scientific solutions for clients We offer integrated solutions across research, development and manufacturing Sector expertise include pharmaceuticals, biotech, nutrition, animal health, consumer goods and specialty chemicals Our team includes more than ~5,600 scientists out of total 8,200+ headcount, operating across 4 global state-of-the-art campuses located in India’s leading life science hubs: Bangalore, Mangalore and Hyderabad & USA (Baltimore) Established track record in discovery research and development/ manufacturing for small and large molecules
Page 8
Our journey so far Putting Science to Work 8 Globalization and strategic collaboration • Expanded into formulations development • Contract with Endo Pharmaceuticals to develop novel anti cancer biological therapeutic molecules • Extension of collaboration with BMS; • Merger of Clinigene • Crossed annual turnover of Rs. 5 Billion Continued investments and growth • Expanded collaboration with BMS, Amgen and Zoetis • Expansion of Integrated Drug Discovery platform • Laboratory capacity expansion in Bangalore and Hyderabad • Expansion in Mangalore for commercial API manufacturing • Capacity and capability addition in Biologics manufacturing • Entered in long-term partnership with Zoetis for Biologics commercial-scale manufacturing • Acquired multi-modal biologics manufacturing facility from Stelis Biopharma Ltd • Acquired 17 acres land in Hyderabad to support long term growth in research business • Acquired, state of the art first biologics site in Baltimore, USA – fitted with multiple monoclonal antibody (mAbs) manufacturing lines taking Syngene’s total single-use bioreactor capacity to 50,000L for large molecule discovery, development, and manufacturing services Foundation • Operations started • Expansion of R&D Lab • Granted 100% EOU status by the Government of India 1993 – 2000 Expansion • Expanded service offerings to include chemical development, safety assessment, biologics development • Collaboration with BMS to set up BBRC, Syngene’s first dedicated R&D Center 2001 – 2009 IPO and further collaborations • IPO and listing • Collaboration with Amgen to set up a dedicated R&D center 2015 – 2018 2010 – 2014 2019 – 2025
Page 9
Key facts and figures Putting Science to Work 9 * All figures are as on March 31, 2025 / FY2025 400+ patents held with clients World class infrastructure International presence with global campuses across Bangalore, Hyderabad and Mangalore in India and Baltimore in USA qualified to meet international standards ~400 active clients 14 out of top 20 pharma companies are clients Rs. 3,642 Cr (~US$430* Mn) FY25 Revenue from operations Rs. 475 Cr** FY25 PAT 8,235 headcount including 5,641 talented scientists 92% energy from renewable sources **before exceptional items
Page 10
Syngene – one of the largest integrated CRDMO players in India 10 One-stop platform for integrated drug discovery, development and manufacturing across modalities Over 50% increase in active clients • Expanded partnership with big pharma companies • Increasing contribution from emerging biotech companies in research services with share of total revenue from US emerging biotech increasing from 10% in FY21 to 14% in FY25 • Expanded into commercial manufacturing in Biologics with Zoetis • Enhanced BD presence across key value clusters including US and Europe • 25-year strategic partnership with BMS – established BBRC, India’s first and largest dedicated R&D center Building partnerships 14 out of top 20 pharma companies are clients More than doubled infrastructure that is qualified to meet international standards • Expanded laboratory capacity in Bangalore and Hyderabad • Expanded to Mangalore for commercial API manufacturing • Acquired land in Hyderabad for long term growth in research business • Acquired multi-modal biologics facility from Stelis Biopharma Ltd • Acquired first biologics site in the USA from Emergent Manufacturing Operations Baltimore, LLC • US FDA, EMA, UK VMD, Health Canada, PMDA approved, AAALAC accredited and GLP certified facilities • 5,600+ scientists comprising PhDs, MS • Skills and experience to become trusted thought partner in cutting-edge research • Scientific prowess across modalities including small molecule, large molecule, peptides, oligonucleotides, antibody drug conjugates, PROTACs • Proven success in delivering integrated CMC programs and clinical candidates Building capabilities for futureExpanding capacity ~3x employees from FY16 comprising talented scientists FY16 FY24 250+ ~400 (#) 3,526 8,235 FY16 FY24 (#)(in Million sq. ft.) FY16 FY25 0.9 2.5+ March’16 March’25 March’16 March’25 March’16 March’25
Page 11
Putting Science to Work 3-pronged growth strategy across diversified platform 11 Discovery Services Flexible Platform with capability across multiple modalities including small molecule, large molecule, peptides, oligonucleotides, antibody drug conjugates, PROTACs SynVent - proprietary platform for Integrated Drug Discovery SARchitect- proprietary platform for data visualization and analysis. Enables collaboration between scientific experts across geographies Large Molecule CDMO Process development Manufacturing of large molecules for clinical/commercial supplies Associated services to demonstrate the safety, tolerability and efficacy of the selected drug candidate cGMP-compliant facilities State-of-the art Biologics manufacturing facilities with international presence Dedicated R&D Centers Ring-fenced infrastructure for exclusive operations for an individual client Dedicated multi-disciplinary team of scientists Access to entire Syngene ecosystem for specialist research and development operations Small Molecule CDMO Drug substance and drug product development Associated services to demonstrate the safety, tolerability and efficacy of the selected drug candidate cGMP-compliant manufacturing of clinical supplies, and registration batches for small molecules Manufacturing of small molecules for commercial supplies State-of-the art API manufacturing facility Research Services (CRO) Clinical Development Comprehensive research services through trials conducted on both healthy volunteers and patients Regulated bioanalysis (small & large molecules, peptides, ADC's), Central Lab, Clinical Data Management & Biostatistics as allied services
Page 12
Putting Science to Work 12 Our Strategy Operational Excellence Drive operational excellence through improved reliability, speed and efficiency to enhance customer delivery and satisfaction. People Build a future ready, high-performance organization by nurturing leadership at all levels, fostering holistic employee well-being, and driving a culture of continuous growth and innovation Environmental, Social and Governance (ESG) Syngene is committed to responsible and sustainable growth, ensuring that its ESG standards meet the evolving expectations of clients, investors, and stakeholders. Our ESG strategy is a key enabler of long-term value creation, embedding environmental stewardship, social responsibility, and robust governance across all aspects of our operations Development and Manufacturing Services – Small Molecules Utilize existing Chemistry, Manufacturing, and Controls (CMC) capabilities and commercial manufacturing, while also developing innovative technologies, to establish a fully integrated, cutting-edge small molecule development and manufacturing service provider Research Services Provide an integrated end-to-end therapeutic discovery services Encompassing drug discovery, pre- clinical and clinical development capabilities across technologies, platforms, disciplines, disease areas and therapeutic modalities. Development and Manufacturing Services – Large Molecules Implement a comprehensive strategy for biologics development and manufacturing, establishing a seamless, one-stop-shop capability that covers everything from drug discovery to commercial production.
Page 13
3 Syngene strengths
Page 14
Syngene strengths Putting Science to Work 14 A global scale CRDMO player • Integrated Drug Discovery, Development and Manufacturing service provider • Small and large molecules, ADCs, oligonucleotides • Listed on Indian Stock Exchanges (NSE and BSE) Science in our DNA • Global presence : India life science hubs: Bangalore, Mangalore and Hyderabad & Baltimore, USA • ~5600+ qualified scientists including ~500 PhDs (8,200+ total headcount) • Resilient supply chain management • 2.5 Mn+ sq. ft world-class R&D and manufacturing infrastructure Solutions through innovation • IP fully assigned to clients • Track record of data management and security • Over 400+ patent filings by clients recognizing Syngene scientists Blue chip client list • ~400 active clients • Partnering with large / mid-size / emerging biopharma and other industries • Clients concentrated in US, Europe & Japan • Track record of working with diverse industry sectors Quality matters • Fully digitized quality organization • Strong compliance track record with global regulators • US FDA, EMA, UK VMD, Health Canada, PMDA approved, AAALAC accredited and GLP certified facilities • 111 client and regulator audits in the last financial year Making a difference • Partnerships have delivered numerous clinical candidates • Delivery history for integrated CMC programs up to clinical trials and beyond
Page 15
Experienced workforce: building capabilities and careers Putting Science to Work 15 Inspiring technical excellence and providing opportunities to grow8,235 total headcount 5,641 scientists delivering high quality solutions – create a competitive edge 7% 51% 42% PhDs Master's Degree Others Empowering our workforce Continuous learning & development Shaping a culture of belonging • Thrive 360: A holistic approach to employee well being addressing physical, mental and emotional, social, financial and professional health through targeted initiatives. • Our corporate initiatives contribute to both professional fulfillment and organizational success. Moving beyond traditional evaluations, our forward-looking approach continues to foster meaningful conversations that celebrate achievements while paving the way for future growth and success • Enhancing managerial and leadership capabilities through our multi-pronged approach which ensures leaders at all levels are equipped to inspire, develop, and retain top talent • Enhancing our technical learning framework by establishing an enterprise-wide Scientific Skills Development Academy. This centralized academy will standardize and elevate our upskilling approach, integrating advanced curricula in emerging research methodologies with hands-on application module • A strong and well-structured Diversity, Equity, and Inclusion strategy lays the groundwork for making Syngene a fair, reputed and high performing organization • We welcome diverse people from different backgrounds, having varied capabilities and offering a wide range of perspectives • 26% of our workforce is female and 6% of senior management positions are held by women All figures are as on March 31, 2025
Page 16
Putting Science to Work 16 Extended our state-of-the-art infrastructure & new capabilities with global presence to meet our strategic partners needs… HQ campus at Bangalore, India 90 Acres (3,64,217 sq. mt) where most of Syngene’s capabilities are housed today Biologics Discovery development & and manufacturing plants in Bangalore, India Fully functional R&D Centre at Genome Valley, Hyderabad, India API manufacturing Commercial manufacturing to support product launch located at Mangalore, India USA based Biologics facility Bayview, Baltimore, USA
Page 17
• Customers receive ring-fenced infrastructure customized to their research needs • Dedicated scientific and support teams work exclusively on the customer’s projects • Long-term strategic partnerships, typically extending for five years or more, foster deep collaboration and sustained innovation • A dedicated team of scientific personnel from predefined disciplines works exclusively on the customer’s projects • Deliverables and team composition evolve as the project progresses to align with changing requirements • Agreements are typically renewed annually, ensuring continuity and flexibility • Services are provided within a defined scope • Flexible, on-demand personnel and research infrastructure are allocated to meet project objectives • Engagements can be short- term or long-term, based on project requirements • A milestone-driven approach covering a portfolio of research projects • Customers benefit from reduced upfront costs, with payments tied to predefined success milestones … and are open to any single or combination of above Dedicated R&D Labs Full time equivalent (FTE) Fee For service (FFS) Outcome – based model with Service Level Agreement Risk / Reward Model • A contract structured around the achievement of predefined outcomes • Linked to specific productivity goals to ensure performance-driven results Putting Science to Work 17 We currently operate a range of successful collaboration models 5
Page 18
Putting Science to Work 18 Our experience spans multiple industry segments and partners us with global leaders across the world… Large & Mid-Sized BioPharma Emerging BioPharma (EBP) Animal Health AgroChem CPG Chemicals/ Polymers Note : This is a representative selection of the customers Syngene works with. We work with ~ 400 customers across industry segments .All product names, logos, brands, trademarks and registered trademarks are the property of their respective owners
Page 19
Operational robustness driving strategy execution Putting Science to Work 19 Focused execution through strong Project Management Structured program management for executing client projects enabled by SynPro platform and SynPro Academy ensuring delivery of client projects Digital as a differentiator AI capability in all research teams Integrating automation, IT solutions, and data analytics, we optimize workflows, enhance resource allocation and utilization, and ensure regulatory compliance Strategic Sourcing that makes a difference Effective global collaboration with 2,800+ suppliers across 30 countries China-independent supply chain development continued through strategic sourcing from the Indian ecosystem, and engagement with global suppliers to establish operations in India Continuous improvement embedded in operations driven by certified operational leaders Six Sigma Black Belt certified staff in each service line and support function Green belt certified staff across operations 99% of employees white belt certified Quality management system: digitized and audit-ready 111 customer and regulator audits in the last financial year 5 successful USFDA audits in the last 5 years Client-focused commercial organization Leaders based in the US, Europe, UK and Asia close to client locations
Page 20
Putting Science to Work 20 Syngene digital initiatives aimed at driving innovation and operational Automate workflows, eliminate errors, and improve execution quality Driving Enterprise- Wide Transformation Strengthening Scientific Operations Enabling AI- Powered Productivity Fortifying Infrastructure and Information Security Comprehensive 1-3-5-year roadmap to future-proof operations and build next- generation digital capabilities, with an emphasis on AI adoption A key initiative, Project VEGA, aims to automate and integrate core business processes, enhancing Syngene’s digital presence and customer engagement. “Fail fast” approach to AI and GenAI, launching small-scale pilots to quickly test feasibility, assess early outcome Advanced IT and cybersecurity landscape with a One-Click Disaster Recovery system, CDC & ISWG At Syngene, IT strategy is closely aligned with organizational priorities, emphasizing investments in automation and digitization to improve scientific and enterprise functions. Certification as per ISO 13485:2016, ISO/IEC 27001 and ISO 9001:2015 requirements Accelerating Digital Transformation at Syngene
Page 21
Committed to safety and sustainability Putting Science to Work 21 Safety is our first priority • Accredited with ISO 45001:2018 for Occupational Health and Safety (OH&S) measures • Risk assessments are an integral part of our operation • Kavach, our flagship safety program, has delivered improvement in safety metrics and drives focus on industrial safety for all employees • Lost time injury frequency rate (LTIFR ): 0.00 • 36,737 hours of EHSS training Committed to environmental protection • Committed to Science-based targets for greenhouse gases • 95% of total hazardous and non-hazardous waste recycled • 92% of energy procured from green energy sources • 1,296 MT equivalent CO2 savings from energy conservation • 73,207 MT equivalent CO2 reduction in GHG emissions • 64% YoY freshwater savings achieved • 1,04,413 KL fresh water saved from recycling, reusing and rainwater harvesting • 11,433 KL water rainwater harvested Refer to the CSR link on our website to know about our corporate social responsibility pursuits on healthcare, education, environment, rural development Refer to the Annual Report on our website to know more All figures are as on March 31, 2025, unless otherwise specified ESG Ratings ESG Rating Agency 2025 2024 Ecovadis Silver Bronze CDP Climate Action – ‘B’ Water Security- ‘B’ Climate Action – ‘C’ Water Security- ‘D’ Sustainalytics 12.4 Low Risk 12.4 Low Risk MSCI A BBB
Page 22
Accreditations Putting Science to Work 22 • USFDA, EMA, UK VMD, PMDA and Health Canada Certified GMP facilities. • GLP , NABL (ISO IEC 17025) certification for Safety Assessment and Large Molecule Bioanalytical Laboratory • GLP certification for Viral Testing Facility, AAALAC Accreditation and CCSEA registration for Safety Assessment • USFDA, MHRA. AGES inspected & ANVISA approved Translational and Clinical research facility • ISO 15189:2012, NABL & College of American Pathologists (CAP) accredited Clinical and Molecular diagnostics facility • ISO 9001:2015, 14001:2015, 45001:2018 and ISO/IEC 27001:2022 accreditations.
Page 23
We have consistently received industry recognition for our scientific capability and business excellence 20232022 • Dream Companies to Work Award at the 29th Edition of the World HRD Congress Awards. • Asian Leadership Award for Excellence in Branding and Marketing in the Contract Research Development and Manufacturing category • CRISIL awards Syngene Top score among Indian Pharma - for Environment Safety Governance (ESG) • Syngene ranked #69 in Fortune India magazine's list of 'Top 100 Indian wealth creators 2021’ • India Pharma Awards 2021 for Operational Excellence–Manufacturing organized by Informa Markets, India • Best Governed Company in the Listed Segment: Medium Category at the 21st National Awards for Excellence in Corporate Governance by The Institute of Company Secretaries of India (ICSI) • Best Corporate Foundation Award at the World CSR Congress 2024 • CMO Leadership Awards 2022 Presented by Life Science Leader and Outsourced Pharma • CMO Leadership Award Champion 2022 - Presented by Life Science Leader and Outsourced Pharma • Golden Peacock Award for Excellence in Corporate Governance for 2021 by the Institute of Directors at the 'Golden Peacock Awards Ceremony’ • The 2022 Brandon Hall Group HCM Excellence Bronze Award In Leadership Development for ‘Best Unique or Innovative Leadership Program’ and ‘Best Advance in Compliance Training’ • The 2022 Brandon Hall Group HCM Excellence Bronze Award In Leadership Development for • Asia Pacific Biologics CMO Excellence Awards 2022 - For Quality • Biopharma Honours Award 2022 - For Viral Testing Facility by Informa Markets • Most Preferred Workplace 2022 - Award by MarksmenDaily.com • EcoVadis Sustainability Rating, 2024 : Syngene secured silver rating in the EcoVadis sustainability index for commitment to ESG practices and ranked among the top 15% of companies assessed worldwide. • Asia Pacific Biologics CMO Excellence Awards 2024 : Adjudged Best Biologics CMO in South Asia by IMAPAC • Winner under the Reliability and Compatibility categories for exceeding customer expectations at CDMO Leadership Awards 2024 • Declared champion by the Institute of Supply Chain Management (ISCM) at the Pharma Supply Chain Management 5.0 summit. • Award for Excellence in Environment Health and Safety (EHS) practices at CII-SR EHS Excellence Awards 2023 • Awarded India’s Best Managed Company by Deloitte • Golden Peacock Award 2023: For risk management practices under the Pharmaceutical sector category. • Best Overall Sustainable Performance (Pharmaceutical) 2023 at the 2nd Edition India Sustainability Conclave & Awards 2023 2021 Putting Science to Work 23 • Golden Peacock National Quality Award 2023 For meeting the overall requirements of the Golden Peacock Excellence Model • Biopharma Excellence Awards 2023 For Best Contract Development and Manufacturing Organization (CDMO) 2025 • CDMO Leadership Award 2025 : Adjudged winner in the Biologics category by Outsourced Pharma and Life Science Connect publications • Biopharma Excellence Awards 2025 (India Edition) : Adjudged best bioprocessing supplier, analytical services, by IMAPAC. • Pharma Supply Chain Champion (mid-sized firms) 2025 : Declared Pharma Supply Chain Champion among mid-sized pharma and API firms in the Institute of Supply Chain Management (ISCM) rankings for 2025 • ‘World’s Most Sustainable Companies 2025’ by TIME Magazine & Statista : Ranks #1 among Indian pharma & biotech firms , Top 10 among all Indian companies across all sectors & Among the top 20 most sustainable life sciences companies worldwide • NAMC Gold Award for Biologics Manufacturing Excellence at the National Awards for Manufacturing Competitiveness (NAMC) Note : This is a representative selection of awards received by Syngene and is not an exhaustive list
Page 24
Robust risk management framework Putting Science to Work 24 Risk Owner • Continuously identify, assess, and monitor risks • Develop, implement, and update mitigation plans and risk registers • Establish and maintain risk management policies and procedures Executive Committee • Review and recommend enterprise-level risks and framework changes • Oversee and ensure implementation of mitigation plans with defined thresholds • Monitor risk movements, escalate as needed, and support operational execution Risk Management Committee • Approve and oversee the company-wide risk management and business continuity framework • Define risk appetite, tolerance, and critical exposures • Ensure an optimal balance between risk and reward Board of Directors (BOD) • Define and review the company’s risk tolerance and overall policy • Oversee and guide enterprise risk management practices • Ensure alignment with strategic objectives Refer Annual report for complete risk profile and risk mitigation strategy Syngene’s enterprise-wide risk management framework provides a holistic approach to identification, monitoring, reporting and mitigating risks that could impact performance.
Page 25
4 Financials
Page 26
1 ) Other Net Assets calculated as all assets other than cash and cash equivalents less all liabilities other than debt and shareholders equity (2) Net cash / (Net debt) calculated as the Cash & cash equivalents (Cash and bank balances + Current investments+ Fixed deposits) less Total debt (Short-term borrowings + Long-term borrowings) at the end of the year Q2 FY26 financial highlights Putting Science to Work 26 Balance Sheet Highlights Shareholders’ funds 47,349 Net Fixed assets 40,382 Other net assets (1) -3,216 Net cash/(debt) (2) 10,183 Total Use of Funds 47,349 As on 30th September 2025 All figures in Rs. Mn unless otherwise specified Particulars Q2FY26 Q2 FY25 YoY change Q1 FY26 QoQ change Revenue from operations 9,106 8,910 2% 8,745 4% Other income 154 165 -7% 177 -13% Reported revenue 9,260 9,075 2% 8,922 4% Material costs 2,385 2,366 1% 2,177 10% Staff costs 3,072 2,713 13% 2,915 5% Other direct costs 251 241 4% 260 -4% Other expenses 1,285 1,185 8% 1,281 0% Foreign exchange (gain)/loss, net 118 -43 -374% 48 146% EBITDA 2,149 2,613 -18% 2,241 -4% EBITDA Margin 23.2% 28.8% 25.1% Depreciation and Finance Cost 1,297 1,240 5% 1,228 6% PBT 852 1,373 -38% 1,013 -16% Tax 181 312 -42% 146 24% PAT before exceptional items 671 1,061 -37% 867 -23% PAT Margin 7.2% 11.7% 9.7% PAT after exceptional items 671 1,061 -37% 867 -23% All figures in Rs. Mn unless otherwise specified
Page 27
H1 FY26 financial highlights Putting Science to Work 27 All figures in Rs. Mn unless otherwise specified Particulars H1 FY25 H1 FY26 YoY change Revenue from operations 16,807 17,851 6% Other income 346 331 -4% Reported revenue 17,153 18,182 6% Material costs 4,701 4,561 -3% Staff costs 5,237 5,987 14% Other direct costs 496 511 3% Other expenses 2,236 2,567 15% Foreign exchange (gain)/loss, net -10 166 -1806% EBITDA 4,493 4,390 -2% EBITDA Margin 26.2% 24.1% Depreciation and Finance Cost 2,426 2,525 4% PBT 2,067 1,865 -10% Tax 461 327 -29% PAT before exceptional items 1,606* 1,538 -4% PAT Margin 9.4% 8.5% PAT after exceptional items 1,818 1,538 -15% *Excludes exceptional item of Rs. 21 crores (net of tax) in Q1 FY25 relating to final settlement from an insurance claim
Page 28
5 Shareholding and Share Information
Page 29
Syngene and Biocon Group Putting Science to Work 29 Syngene is an operationally independent publicly listed subsidiary of Biocon Limited, established in 1993 as India’s first Contract Research Organization. The Company has 30+ years of experience in novel molecule discovery, development and manufacturing services Integrated services: • Research Services • Development and for • Manufacturing small/large molecules • Product Based • Biosimilars • Formulations and Compounds • Alternative Therapeutic Drugs Biocon Limited, founded in 1978, is an innovation-led global biopharmaceuticals company and has majority holding in key operating entities including Syngene
Page 30
Shareholding and Share Information Putting Science to Work 30 Syngene’s shareholders* Syngene’s Share Information* NSE Ticker SYNGENE BSE Ticker 539268 Market Cap (Rs. Mn) 2,50,971 % free-float^ 47% Free-float market cap (Rs. Mn) 1,18,750 Share Outstanding (Mn) 403 • As on 30th September 2025 • ^ Free float includes shares held by public and in ESOP Trust 53% 47% 1% Promoter & Promoter Group Public ESOP Trust
Page 31
For more details Putting Science to Work 31 Visit our website www.syngeneintl.com IR Contact: Nandini Agarwal / Shubham Jain +91 7838382527 / +91 6377651994 investor@syngeneintl.com nandini.agarwal@syngeneintl.com shubham.jain@syngeneintl.com https://www.linkedin.com/company/syngene-international-limited https://www.youtube.com/channel/UCIC4WSA1k5YAC531gMLkbIQ Media Contact: Shotorupa Ghosh +91 8450977080 shotorupa.ghosh@syngeneintl.com